Review
doi: 10.1210/jcem.84.6.5771.
Relative versus attributable risk of breast cancer from estrogen replacement therapy
Affiliations
- PMID: 10372679
- DOI: 10.1210/jcem.84.6.5771
Item in Clipboard
Review
Relative versus attributable risk of breast cancer from estrogen replacement therapy
J Clin Endocrinol Metab.
1999 Jun.
No abstract available
Similar articles
-
[Alarming data on the risk of breast cancer following estrogen replacement therapy should be interpreted carefully].Lakartidningen. 2005 Apr 18-24;102(16):1217-8. Lakartidningen. 2005. PMID: 15921094 Swedish. No abstract available.
-
[Does menopausal hormonal replacement therapy increase the risk of breast cancer?].Duodecim. 1996;112(12):1110-5. Duodecim. 1996. PMID: 10593013 Review. Finnish. No abstract available.
-
Estrogen replacement therapy and breast cancer.J Reprod Med. 1993 Mar;38(3):183-5. J Reprod Med. 1993. PMID: 8487233 Review.
-
[Hormone replacement therapy and breast cancer].Med Monatsschr Pharm. 2002 Oct;25(10):337-47. Med Monatsschr Pharm. 2002. PMID: 12404946 Review. German. No abstract available.
-
Breast cancer and hormone-replacement therapy: the Million Women Study.Lancet. 2003 Oct 18;362(9392):1331; author reply 1332. doi: 10.1016/S0140-6736(03)14597-7. Lancet. 2003. PMID: 14575992 No abstract available.
Cited by
-
A heartfelt message, estrogen replacement therapy: use it or lose it.Am J Physiol Heart Circ Physiol. 2018 Dec 1;315(6):H1765-H1778. doi: 10.1152/ajpheart.00041.2018. Epub 2018 Sep 14. Am J Physiol Heart Circ Physiol. 2018. PMID: 30216118 Free PMC article. Review.
-
BRCA1 inhibits membrane estrogen and growth factor receptor signaling to cell proliferation in breast cancer.Mol Cell Biol. 2004 Jul;24(13):5900-13. doi: 10.1128/MCB.24.13.5900-5913.2004. Mol Cell Biol. 2004. PMID: 15199145 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
